Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis.

Cancer Med · 2019 · PMC6912062 · PMID 31679184

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Phase 2 trials showed a trend toward higher rates, with 3.89% for all‐grade adrenal insufficiency and 0.48% for serious‐grade adrenal insufficiency (Table 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.